© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Future implications for palliative therapy with selective immunomodulating microtubule binding agents as prevention against chemotherapy-induced neutropenia in high-risk patients with solid tumors.
September 2nd 2021
General considerations surrounding the risk of chemotherapy-induced neutropenia in solid tumors.
Considerations for treatment selection for chemotherapy-induced neutropenia.
September 9th 2021
Implications of severity and sequelae of chemotherapy-induced neutropenia for disease management.
Recommendations for preventing and mitigation infection risk in patients with chemotherapy-induced neutropenia in the adjuvant setting.
September 16th 2021
Current mitigation and management strategies for chemotherapy-induced neutropenia.
Limitations of current therapies available for the prevention and management of chemotherapy-induced neutropenia.
September 23rd 2021
Strategies for prophylaxis against chemotherapy-induced neutropenia in the setting of metastatic disease.
The rationale for studying plinabulin, a first-in-class selective immunomodulating microtubule binding agent, for the prevention of chemotherapy-induced neutropenia.
September 30th 2021
An overview of the Protective-1 trial of single-agent plinabulin vs pegfilgrastim after docetaxel in patients with advanced breast cancer, advanced non–small cell lung cancer, and hormone-refractory prostate cancer.
Implications for using plinabulin as prophylaxis against chemotherapy-induced neutropenia alone or in combination with other therapies based on data revealed by the Protective-1 and Protective-2 trials.